Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$251M+3,686%$209M+2,886%$128M+381%$108M+209%-$7M+79.1%
$9M-35.7%$10M-37.5%$13M-11.9%$14M-3.4%$14M-13.8%
$29M+20.8%$26M+8.3%$27M+16.1%$26M+15.6%$24M+10.3%
-$111M-$27M
$81M+153%$66M+128%$58M+287%$45M+350%$32M+300%
$0$0-100%$0-100%$0-100%
-$80M-305%-$66M-196%-$34M-191%$21M+198%$39M+184%
$148M+144%
$249M+200%
$346M+42.4%$17M-92.9%$250M+4,900%$247M+3,429%$243M+2,330%
-$6M-$30M
-$197M-259%-$124M-4,233%$159M+211%$206M+185%$124M+130%
-$192M-$93M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?
Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.